Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
2 Dividend Stocks to Double Up On Right Now
02:45pm, Tuesday, 20'th Sep 2022 The Motley Fool
These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.
Company News for Sep 20, 2022
01:36pm, Tuesday, 20'th Sep 2022 Zacks Investment Research
Companies in The News Are: WIX,COIN,TBPH,GSK,MRNA
2 Dividend Stocks to Double Up On Right Now
10:45am, Tuesday, 20'th Sep 2022
These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.
Haleon impresses with results and rejection of indemnity requests from GSK and Pfizer
08:19am, Tuesday, 20'th Sep 2022
Haleon PLC (LSE:HLN, NYSE:HLN) shares recouped some of their losses since being spun out of GSK earlier this year as the consumer healthcare group rejected any liability in the Zantac lawsuits that ha
Haleon rejects Zantac indemnification requests from GSK, Pfizer
02:17am, Tuesday, 20'th Sep 2022
Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.
WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19
06:58pm, Friday, 16'th Sep 2022 Zacks Investment Research
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
Pfizer's (PFE) Late-Stage Meningococcal Jab Study Meets Goal
05:41pm, Friday, 16'th Sep 2022 Zacks Investment Research
Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.
GSK (GSK) Stock Moves -0.58%: What You Should Know
09:50pm, Thursday, 15'th Sep 2022 Zacks Investment Research
GSK (GSK) closed the most recent trading day at $31.02, moving -0.58% from the previous trading session.
GSK 'sell' rating removed as Zantac liabilities expected to be US$5bn
07:44am, Thursday, 15'th Sep 2022
GSK PLC (LSE:GSK, NYSE:GSK) has been upgraded by Credit Suisse on the assumption that its potential liability for Zantac lawsuits will be much smaller than the US$12bn that has been wiped from its mar
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
10:00pm, Wednesday, 14'th Sep 2022 Zacks Investment Research
GSK (GSK) closed the most recent trading day at $31.20, moving -1.36% from the previous trading session.
Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players
09:44pm, Tuesday, 13'th Sep 2022 Zacks Investment Research
Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.
Pharma Stock Roundup: FDA Nod to AZN's Imfinzi for New Cancer & Other Updates
05:20pm, Friday, 09'th Sep 2022 Zacks Investment Research
FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.
GSK (GSK) Gains But Lags Market: What You Should Know
09:50pm, Thursday, 08'th Sep 2022 Zacks Investment Research
In the latest trading session, GSK (GSK) closed at $31.51, marking a +0.06% move from the previous day.
SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma
04:54pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.
Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival
03:53pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.
